Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants
| Status: | Completed |
|---|---|
| Conditions: | Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 49 |
| Updated: | 4/21/2016 |
| Start Date: | June 2014 |
| End Date: | July 2014 |
A Phase 1 Clinical Study to Assess the Effect of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Subjects
The purpose of this study is to determine whether multiple doses of darunavir/ritonavir or
lopinavir/ritonavir affect the pharmacokinetics of daclatasvir in healthy participants.
lopinavir/ritonavir affect the pharmacokinetics of daclatasvir in healthy participants.
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com
Key Inclusion Criteria:
- Healthy male and female participants, aged 18 to 49, as determined by medical
history, physical examination, 12 lead electrocardiogram, vital signs, and clinical
laboratory evaluations
Key Exclusion Criteria:
- Any significant acute or chronic medical illness; donation of blood to a blood bank
or in a clinical study (except a screening visit) within 4 weeks of study drug
administration (within 2 weeks for plasma only); or blood screen findings positive
for hepatitis C antibody, hepatitis B surface antigen, or HIV-1 and HIV-2 antibodies
We found this trial at
1
site
Click here to add this to my saved trials
